CDK4 and sarcoma: Targets were detected: CDK4 amplification, copy number 16.0, and MDM2 amplification, copy number 28.0, with NCCN guidelines suggesting that 12q13-15 (CDK4, MDM2) amplification may be a molecular feature of dedifferentiated lipo sarcoma; CDK4 amplification, copy number 16.0, suggests potential sensitivity to Palbociclib (pipercetillin); MDM2 amplification, copy number 28.0, suggests sensitivity to Milademetan (DS-3032).